

PRESS RELEASE – NEW WEBSITE LAUNCH ANNOUNCEMENT

COURNON D’AUVERGNE, France – March, 9th 2022

Lumibird Medical, leader in ophthalmic laser, today announces its new website:

www.glaucoma-laser-assisted-solutions.com dedicated to laser therapies for each glaucoma stage.

As a world leader in lasers in Ophthalmology, Lumibird Medical offer a comprehensive approach to Glaucoma Laser Therapy with treatment options at every stage of the disease paradigm:

1. **SLT** - *A first-line treatment for Glaucoma*: SLT is a unique, non-destructive & repeatable laser therapy, reducing intraocular pressure in patients with primary open angle glaucoma. The LIGHT study, published in 2019, confirms SLT as a first line treatment, delivering efficacy and some cost saving benefit to patients. The study demonstrated an improvement in quality-of-life survey in contrast to other therapeutic options.
2. **SUBCYCLO** – *A Second-Line Therapy for Glaucoma*: SubCyclo® is a subthreshold laser-therapy for the treatment of glaucoma. Based on the transscleral cyclophotocoagulation principle, SubCyclo® stimulates the ciliary body with an intermittent 810nm laser wavelength, resulting in a reduction of aqueous humor production, while also remodelling the uveoscleral pathway, to provide an improved secondary route of aqueous outflow.
3. **THERMOCYCLO** – *A last Resort Therapy for Glaucoma*: A well-established transscleral laser treatment modality indicated for refractory glaucoma patients. Transscleral photocoagulation of the ciliary processes reduces overall production of aqueous humor.

In order to promote a better understanding of these laser technologies and their clinical applications, Lumibird Medical has created the www.glaucoma-laser-assisted-solutions.com website, as a concise repository where clinical evidence and best practice resources can be easily accessed online. The website is available in English with a Spanish edition to follow in April.

About Lumibird Medical

Lumibird Medical is the medical holding of the Lumibird Group, the global leader in the development of solid-state lasers for scientific and industrial use. Lumibird Medical provides ophthalmologists with therapeutic laser solutions to treat the four main causes of blindness: glaucoma, cataracts, diabetic retinopathy and macular degeneration. Its products are available for direct purchase and via 100 independent distributors in over 110 countries. It comprises Quantel Medical (France and Polska) and Ellex (Australia, Japan and US), since July 2020, along with Optotek Medical in Slovenia and Lumibird Medical Nordics (Sweden, Finland and Norway).

Press contact: Stephanie Belot: sbelot@quantelmedical.fr

